HRT and Breast Cancer Risk: What the Evidence Says in 2026

Hormone Replacement Therapy (HRT) is widely used to manage symptoms of menopause, including hot flushes, night sweats, mood changes and sleep disruption. At the same time, it is also one of the most discussed treatments when it comes to breast cancer risk. With guidance and research continuing to evolve, it can help to gain an understanding of what the evidence actually shows in 2026, and how that applies to real-life decisions about menopause care.

This article looks at what current research and UK guidance say about HRT and breast cancer risk, and how to make sense of the information when considering your own options.

Understanding HRT and why it is used

HRT works by replacing hormones that naturally decline during menopause, mainly oestrogen and progesterone. These hormones play a role in many bodily functions, including temperature regulation, sleep, bone health and mood.

During menopause, changes in hormone levels can lead to symptoms that affect daily life, which is why HRT is commonly used to help manage them. NHS guidance continues to support HRT as an effective option for managing menopausal symptoms when used appropriately.

However, like any medical treatment, it is important to understand both the benefits and the potential risks.

What does the evidence say about breast cancer risk?

Research over the last two decades has shown a consistent pattern when it comes to HRT and breast cancer risk.

UK regulatory guidance and clinical reviews show that some types of HRT are associated with a small increase in breast cancer risk, particularly combined HRT (oestrogen and progestogen taken together).

Key findings from UK and international research include:

• The increase in risk is generally small for short-term use
• Risk tends to rise with longer duration of use
• Combined HRT is associated with a higher risk than oestrogen-only HRT
• Oestrogen-only HRT is not linked with the same level of increased risk for many women, according to NHS guidance

Research shows that current use of combined HRT is associated with a small increase in breast cancer risk compared with non-use, with risk increasing the longer treatment continues. Importantly, most UK guidance continues to emphasise that the absolute risk remains low for many women, particularly those under 60 using HRT for symptom relief.

Putting the risk into context

Risk is often easier to understand when it is put into everyday terms.

For example, NHS information explains that for combined HRT used over around five years, there may be a small number of additional breast cancer cases per 1,000 women.

This does not mean HRT causes breast cancer in most users. Instead, it reflects a small change in overall likelihood, which varies depending on factors such as:

• Type of HRT
• Length of use
• Age when starting treatment
• Individual risk factors such as family history and lifestyle

This is why decisions about HRT are usually individual rather than one-size-fits-all.

Does HRT affect everyone in the same way?

Not everyone responds to HRT in the same way, and risk is not uniform across all users. Some of the main factors that influence risk include:

Type of HRT - Combined HRT is generally associated with a slightly higher risk compared with oestrogen-only HRT, which is typically used for people who have had a hysterectomy.

Duration of use - Evidence suggests that risk may increase the longer HRT is used, particularly beyond five years.

Individual health profile - Personal factors such as BMI, alcohol intake, physical activity levels and family history can also influence baseline breast cancer risk, independent of HRT use.

This is why clinicians usually review HRT regularly and consider the lowest effective dose for symptom control.

Current UK guidance in 2026

UK guidance continues to support HRT as an effective treatment option for menopausal symptoms when appropriate.

NHS guidance highlights that for many women under 60, the benefits of HRT are likely to outweigh potential risks, particularly when symptoms are affecting quality of life. (nhs.uk)

At the same time, NHS and UK clinical guidance recommend that anyone taking HRT is fully informed about potential risks and reviewed regularly during treatment.

Why awareness and monitoring matter

Because breast cancer risk is influenced by multiple factors, awareness and monitoring remain important regardless of whether someone chooses HRT.

This includes:

• Attending routine breast screening when invited
• Being aware of changes in breast tissue
• Discussing family history with a GP
• Reviewing HRT use regularly if prescribed

For many people, having access to clearer information about hormone levels can also support more informed decisions about menopause management.

Understanding your hormones alongside menopause

Symptoms such as fatigue, mood changes, weight changes and sleep disruption are often linked with menopause, but they can also overlap with other hormone imbalances. For more information, read our complete guide to what is menopause.

Testing can be helpful in building a clearer picture of what is happening in the body, rather than relying on symptoms alone.

The Bluecrest Wellness Advanced Menopause Profile is designed to provide detailed insight into key hormones linked with menopause and overall wellbeing.

It can help identify where hormone levels sit, support conversations with a GP, and provide a clearer baseline when considering options such as HRT or lifestyle changes.

Check your hormone health

If you are currently taking HRT, considering it, or simply want a better understanding of your hormone balance during menopause, a private blood test can provide useful insight.

The Advanced Menopause Profile from Bluecrest Wellness offers a straightforward way to understand your hormone levels, with results explained in a clear, easy-to-read report.

Appointments are available across the UK with no GP referral required, making it easier to take a proactive approach to your health and wellbeing during menopause.

BOOK NOW

Need help? Call free on 0800 652 2183 to speak to one of our team.